Skip to main content
Equibles
XERS logo

XERS · Xeris Biopharma Holdings, Inc.

Track XERS — free

Use XERS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about XERS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.60 +0.27 (+3.24%) At close · Aug 14
Market Cap
$1.57B
Shares
182.32M

Xeris Biopharma Holdings, Inc. Earnings Call Transcripts

Every quarterly earnings call for Xeris Biopharma Holdings, Inc. (XERS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲168.8% $29.73M −$21.83M '22 Q3 22-11-09 ▲54.7% $33.14M −$12.93M '22 Q4 23-01-05 ▲50.4% $33.20M −$16.83M '23 Q1 23-05-09 ▲50.2% $38.01M −$19.84M '23 Q2 23-08-08 ▲62.6% $48.32M −$12.19M '23 Q3 23-11-09 ▲33.9% $44.39M −$13.39M '23 Q4 24-03-06 ▲22.4% $40.64M −$18.98M '24 Q1 24-05-09 ▲26.5% $48.06M −$15.01M '24 Q2 24-08-08 ▲12.3% $54.27M −$15.74M '24 Q3 24-11-08 ▲35.4% $60.10M −$5.11M '24 Q4 25-01-10 ▲47.9% $60.12M −$9.22M '25 Q1 25-05-08 ▲48.8% $71.54M −$1.93M '25 Q2 25-08-07 ▲37.1% $74.38M $621,000 '25 Q3 25-11-06 ▲42.8% $85.81M $11.08M '25 Q4 26-03-02 ▲38.3% $83.13M $2.23M '26 Q1 26-05-07 LATEST ▲28.7% $92.10M −$31.10M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Xeris Biopharma Holdings, Inc. Q2 FY2026 Earnings Call
Revenue
$92.10M
▲ 28.7% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Xeris Biopharma Holdings, Inc. Q1 FY2026 Earnings Call
Confident tone Recorlev growth and commercial expansion Gvoke Medicare headwinds and recovery Financial discipline and capital allocation
Revenue
$83.13M
▲ 38.3% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Xeris Biopharma Holdings, Inc. Q4 FY2025 Earnings Call
Confident tone Recorlev growth and commercial expansion XP-8121 Phase III pipeline 2026 revenue guidance and R&D investment
Revenue
$85.81M*
▲ 42.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Xeris Biopharma Holdings, Inc. Q3 FY2025 Earnings Call
Confident tone RECORLEV growth and franchise Pipeline: XP-8121 (levothyroxine) Financial performance and profitability
Revenue
$74.38M
▲ 37.1% YoY
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Xeris Biopharma Holdings, Inc. Q2 FY2025 Earnings Call
Confident tone Recorlev growth and Cushing's/hypercortisolism market Gvoke performance and growth runway XP-8121 pipeline asset for hypothyroidism
Revenue
$71.54M
▲ 48.8% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Xeris Biopharma Holdings, Inc. Q1 FY2025 Earnings Call
Confident tone Gvoke performance XP-8121 pipeline and investor day Recorlev growth and commercial momentum
Revenue
$60.12M
▲ 47.9% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Xeris Biopharma Holdings, Inc. Q4 FY2024 Earnings Call
Confident tone Recorlev growth 2025 financial guidance Gvoke commercial performance
Revenue
$60.10M*
▲ 35.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Xeris Biopharma Holdings, Inc. Q3 FY2024 Earnings Call
Confident tone Recorlev commercial growth Gvoke performance and share gains Keveyis durability against generics
Revenue
$54.27M
▲ 12.3% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Xeris Biopharma Holdings, Inc. Q2 FY2024 Earnings Call
Confident tone Recorlev performance in Cushing's syndrome Gvoke glucagon franchise Keveyis franchise resilience post-orphan exclusivity
Revenue
$48.06M
▲ 26.5% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Xeris Biopharma Holdings, Inc. Q1 FY2024 Earnings Call
Confident tone Total revenue growth and raised guidance Gvoke and Change Healthcare cyber breach impact Severe hypoglycemia and co-prescribing of rescue therapy
Revenue
$40.64M
▲ 22.4% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Xeris Biopharma Holdings, Inc. Q4 FY2023 Earnings Call
Confident tone Recorlev Cushing's syndrome Gvoke glucagon franchise Keveyis and generic competition
Revenue
$44.39M*
▲ 33.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Xeris Biopharma Holdings, Inc. Q3 FY2023 Earnings Call
Revenue
$48.32M
▲ 62.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Xeris Biopharma Holdings, Inc. Q2 FY2023 Earnings Call
Revenue
$38.01M
▲ 50.2% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Xeris Biopharma Holdings, Inc. Q1 FY2023 Earnings Call
Revenue
$33.20M
▲ 50.4% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Xeris Biopharma Holdings, Inc. Q4 FY2022 Earnings Call
Revenue
$33.14M*
▲ 54.7% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Xeris Biopharma Holdings, Inc. Q3 FY2022 Earnings Call
Revenue
$29.73M
▲ 168.8% YoY
Diluted EPS
$-0.16
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Xeris Biopharma Holdings, Inc. Q2 FY2022 Earnings Call
Revenue
$25.31M
▲ 184.1% YoY
Diluted EPS
$-0.19
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Xeris Biopharma Holdings, Inc. Q1 FY2022 Earnings Call
Revenue
$22.07M
▲ 169.3% YoY
Diluted EPS
$-0.25
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Xeris Biopharma Holdings, Inc. Q4 FY2021 Earnings Call
Revenue
$21.43M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Xeris Biopharma Holdings, Inc. Q3 FY2021 Earnings Call
Revenue
$11.06M
▲ 17.6% YoY
Diluted EPS
$-0.39
Gross margin
70.9%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Xeris Biopharma Holdings, Inc. Q2 FY2021 Earnings Call
Revenue
$8.91M
Diluted EPS
$-0.41
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Xeris Biopharma Holdings, Inc. Q1 FY2021 Earnings Call
Revenue
$8.20M
Diluted EPS
$-0.30
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Xeris Biopharma Holdings, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Xeris Biopharma Holdings, Inc. Q3 FY2020 Earnings Call
Revenue
$9.40M
Gross margin
70.4%
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Xeris Biopharma Holdings, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Xeris Biopharma Holdings, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1867096 CUSIP 98422E103 13F (30d) 231 filings 226 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)